Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Lisa Taylor Ash joins Board of Directors, strengthening operational, regulatory and commercial expertise DUBLIN and LONDON, April 15, 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Stuart Milstein as Chief Platform Officer and Lisa Taylor Ash to its Board of Directors, strengthening the Company's leadership as it advances its antibody-oligo conjugate (AOC) platform towards the clinic. Building on Aerska's recent $39 million Series A financing , the Company is deepening its expertise in RNA interference (RNAi) platform innovation and drug development and strengthening its operations and governance, adding two leaders with track records of translating RNA science into transformative medicines. “Advancing the optimal brain shuttle platform for siRNA delivery to the CNS demands deep expertise across RNA science, drug development, and organizational leadership,” said Jack O'Meara, C
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple [Yahoo! Finance]Yahoo! Finance
- Brown Advisory Large-Cap Growth Strategy Q1 2026 Portfolio Review [Seeking Alpha]Seeking Alpha
- Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial ResultsBusiness Wire
- RNAi?????2035??25?6,720?????????CAGR9.30%???????????????????????? : ???????????????????? [CNET News]CNET News
- Alnylam Pharmaceuticals (ALNY) had its price target lowered by Truist Financial Corporation from $515.00 to $505.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 4/7/26 - Form 4
- 4/7/26 - Form 3
- 4/6/26 - Form ARS
- ALNY's page on the SEC website